Interleukin 1 genotypes in multiple sclerosis and relationship to disease severity

Area of Science:

• Immunogenetics
• Neurology
• Genetics

Background:

• Multiple sclerosis (MS) is a chronic neurological disease with variable clinical outcomes.
• The role of inflammatory cytokines, such as interleukin-1 (IL-1), in MS pathogenesis is increasingly recognized.
• Genetic predisposition may influence disease severity and progression in MS.

Purpose of the Study:

• To investigate the association between specific genetic variants of IL-1alpha, IL-1beta, and IL-1 receptor antagonist (IL-1RN) and the clinical outcome in patients with MS.
• To determine if IL-1 genotypes can predict long-term prognosis in multiple sclerosis.
• To explore the potential of genetically determined immunomodulation via IL-1 in influencing MS progression.

Main Methods:

• Genotyping of single nucleotide polymorphisms (SNPs) in IL-1alpha and IL-1beta, and a variable number tandem repeat (VNTR) in IL-1RN.
• Analysis of clinical outcomes in a cohort of 377 MS patients.
• Logistic regression analysis, corrected for gender, age of onset, and disease duration.
• Validation of findings in an independent cohort of 67 primary progressive MS patients.

Main Results:

• Significant associations were identified between specific IL-1 genotypes and clinical outcomes in MS patients.
• These associations remained significant after adjusting for key demographic and disease parameters.
• The observed trends were replicated in a separate cohort of primary progressive MS patients, confirming the findings.

Conclusions:

• Genetically determined variations in the IL-1 system are associated with long-term clinical outcomes in multiple sclerosis.
• IL-1-mediated immunomodulation appears to play a role in influencing the prognosis of MS.
• These findings suggest that IL-1 genotypes could serve as potential biomarkers for predicting MS disease progression.